Pulmonary Embolism

**

Overview

Pulmonary embolism (PE) occurs when an embolus—most often a fragment of a deep‑vein thrombosis (DVT) from the legs or pelvis—travels through the venous system, passes the right side of the heart, and lodges in a pulmonary artery. The obstruction reduces blood flow to lung tissue, impairing gas exchange and placing acute strain on the right ventricle. Classic symptoms include sudden shortness of breath, pleuritic chest pain (sharp pain that worsens with inspiration), and hemoptysis (coughing up blood). Many patients also present with signs of a DVT, such as a swollen, red, warm, and painful leg. Physical examination may reveal tachypnea, tachycardia, hypoxemia, and occasionally a low‑grade fever. In severe cases, massive obstruction can precipitate obstructive shock, profound hypotension, loss of consciousness, and sudden death. Because the presentation can mimic other cardiopulmonary conditions, a high index of suspicion and prompt diagnostic work‑up are essential.

History/Background

The concept of embolic disease dates to the 19th century, when Rudolf Virchow described the “triad” of stasis, endothelial injury, and hypercoagulability that predisposes to clot formation. The term “pulmonary embolism” entered the medical lexicon in the early 1900s, following autopsy studies that linked sudden death to occluded pulmonary arteries. In 1935, the first systematic clinical description of PE was published by Dr. Charles H. Miller, who correlated leg swelling with respiratory collapse. The development of ventilation‑perfusion (V/Q) scanning in the 1950s and computed tomography pulmonary angiography (CTPA) in the 1990s revolutionized diagnosis, shifting PE from a largely post‑mortem finding to a treatable emergency. Anticoagulant therapy, first with heparin and later with oral vitamin K antagonists, became standard in the 1960s; the introduction of direct oral anticoagulants (DOACs) in the 2010s further simplified management.

Key Information

- Etiology: Over 90 % of PEs arise from DVTs in the deep veins of the lower extremities; other sources include fat, air, amniotic fluid, or tumor fragments. - Risk factors: Prolonged immobility (e.g., long flights, postoperative recovery), malignancy, inherited thrombophilias, hormonal therapy, pregnancy, obesity, and recent major surgery. - Classification: Subsegmental* (distal) – small peripheral arteries. Segmental* – middle‑size branches. Massive (now termed high‑risk*) – obstruction causing sustained hypotension, shock, or cardiac arrest. - Diagnostic work‑up: 1. Clinical prediction scores (Wells, Geneva) to estimate pre‑test probability. 2. D‑dimer testing—high sensitivity, low specificity; a negative result can rule out PE in low‑risk patients. 3. Imaging: CTPA is the gold standard; V/Q scan is used when contrast is contraindicated. 4. Echocardiography may reveal right‑ventricular strain in massive PE. - Management: Immediate anticoagulation (unfractionated heparin, low‑molecular‑weight heparin, or a DOAC) is the cornerstone. High‑risk patients may require systemic thrombolysis, catheter‑directed therapy, or surgical embolectomy. Long‑term secondary prevention involves continued anticoagulation for 3–6 months or longer, depending on recurrence risk. - Prognosis: Mortality ranges from <1 % in low‑risk PE to >30 % in massive, untreated cases. Early recognition and treatment dramatically improve outcomes.

When to seek professional care: Any sudden onset of unexplained shortness of breath, chest pain that worsens with breathing, coughing up blood, or leg swelling should prompt immediate medical evaluation, ideally at an emergency department. Delay can be fatal.

Significance

Pulmonary embolism is a leading cause of cardiovascular death worldwide, ranking alongside myocardial infarction and stroke. Its impact extends beyond acute mortality; survivors may develop chronic thromboembolic pulmonary hypertension (CTEPH), a debilitating condition that can require lifelong therapy or lung transplantation. Public health initiatives that promote early mobilization after surgery, prophylactic anticoagulation in high‑risk patients, and awareness of DVT signs have reduced incidence in many settings. Moreover, advances in imaging and the availability of DOACs have streamlined diagnosis and treatment, decreasing hospital stays and healthcare costs. Understanding PE underscores the interconnectedness of venous health, systemic inflammation, and cardiopulmonary physiology, reinforcing the need for multidisciplinary care and patient education.

INFOBOX:
- Name: Pulmonary Embolism
- Type: Acute Vascular Occlusive Disorder
- Date: First clinical description 1935 (term popularized early 20th century)
- Location: Pulmonary arterial tree (any lung segment)
- Known For: Sudden blockage of lung arteries leading to impaired gas exchange and potential fatality

TAGS: pulmonary embolism, deep vein thrombosis, thromboembolism, anticoagulation, cardiopulmonary emergency, V/Q scan, CT pulmonary angiography, chronic thromboembolic pulmonary hypertension